NCT01066468View on ClinicalTrials.gov

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2011

Conditions
Chronic Myeloid Leukemia (CML)Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
Interventions
DRUG

Gleevec/Glivec

Trial Locations (1)

117997

Novartis Investigative Site, Moscow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY